Related Experiment Video
Updated: Jun 1, 2025
07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
5.2K
Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications
Eoin N Blythe1, Christy Barreira2, Corby Fink1
1Department of Microbiology & Immunology and Robarts Research Institute, University of Western Ontario, London, Ontario N6A 5B7, Canada.
Antibody Therapeutics
|January 22, 2025
Summary
Humanized anti-CD11d antibodies were developed to target CD11d/CD18 integrins for treating inflammatory conditions. These antibodies show therapeutic potential in neurotrauma models and provide new tools for studying CD11d biology.
Area of Science:
- Immunology
- Neuroscience
- Drug Development
Background:
- CD11d/CD18 integrin is a target for treating neurotrauma, sepsis, and atherosclerosis.
- Murine anti-human CD11d antibodies have shown efficacy in rodent neurotrauma models.
- Humanized anti-CD11d monoclonal antibodies represent a progression in CD11d-targeted therapeutics.
Purpose of the Study:
- To develop and characterize humanized anti-CD11d monoclonal antibodies.
- To assess the binding, affinity, and signaling effects of these antibodies.
- To evaluate the in vivo therapeutic potential in a rat spinal cord injury model.
Main Methods:
- Flow cytometry and western blotting were used to analyze antibody binding and cell signaling.
- THP-1 monocytic cell line and primary human leukocytes were utilized.
- A rat spinal cord injury model assessed in vivo therapeutic function.
Main Results:
- Humanized anti-CD11d clones bind human monocytes and neutrophils.
- Clone anti-CD11d-2 binds CD11d/CD18 in active and inactive states without inducing inflammatory signaling.
- A discrepancy between total and surface CD11d/CD18 expression was observed.
Conclusions:
- Humanized anti-CD11d monoclonal antibodies are developed as novel tools.
- These antibodies can be used to study CD11d biology.
- Targeting CD11d offers potential for treating inflammation in acute neurotrauma.
